RSK2 and its binding partners: an emerging signaling node in cancers

Area of Science:

• Molecular Biology
• Cancer Research
• Cell Signaling

Background:

• Mitogen-activated protein kinase (MAPK) pathways are critical in cancer development and therapeutic agent discovery.
• Ribosomal S6 Kinase 2 (RSK2), downstream of ERKs, has been understudied in human diseases except for Coffin-Lowry syndrome.
• RSK2's role in cancer signaling and its potential as a therapeutic target are gaining attention.

Purpose of the Study:

• To elucidate the comprehensive role of RSK2 in cancer development.
• To detail RSK2's binding partners, signaling network, and crosstalk.
• To establish a new paradigm for RSK2 as a central signaling node.

Main Methods:

• Extensive laboratory research over 25 years.
• Elucidation of RSK2 binding partners.
• Analysis of RSK2's signaling network and crosstalk.

Main Results:

• RSK2 acts as a signaling node regulating diverse cellular processes.
• Identified RSK2's modulation of cell proliferation, transformation, and cell cycle.
• Demonstrated RSK2's role in chromatin remodeling, immune response, and inflammation.

Conclusions:

• RSK2 is an emerging and important target for anticancer drug development.
• A deeper understanding of RSK2's mechanism and signaling network is essential to avoid adverse effects of inhibitors.
• RSK2's multifaceted role highlights its significance in cancer biology.